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MaBACKGROUND Proteolytically released extracellular matrix (ECM) fragments, matricryptins, are biologically active and
play important roles in wound healing. Following myocardial infarction (MI), collagen I, a major component of cardiac
ECM, is cleaved by matrix metalloproteinases (MMPs).
OBJECTIVES This study identiﬁed novel collagen-derived matricryptins generated post-MI that mediate remodeling of
the left ventricle (LV).
METHODS Recombinant collagen Ia1 was used in MMPs cleavage assays, the products were analyzed by mass spec-
trometry for identiﬁcation of cleavage sites. C57BL6/J mice were given MI and animals were treated either with vehicle
control or p1158/59 matricryptin. Seven days post-MI, LV function and parameters of LV remodeling were measured.
Levels of p1158/59 were also measured in plasma of MI patients and healthy controls.
RESULTS In situ, MMP-2 and -9 generate a collagen Ia1 C-1158/59 fragment, and MMP-9 can further degrade it. The
C-1158/59 fragment was identiﬁed post-MI, both in human plasma and mouse LV, at levels that inversely correlated to
MMP-9 levels. We synthesized a peptide beginning at the cleavage site (p1158/59, amino acids 1159 to 1173) to inves-
tigate its biological functions. In vitro, p1158/59 stimulated ﬁbroblast wound healing and robustly promoted angio-
genesis. In vivo, early post-MI treatment with p1158/59 reduced LV dilation at day 7 post-MI by preserving LV structure
(p < 0.05 vs. control). The p1158/59 stimulated both in vitro and in vivo wound healing by enhancing basement
membrane proteins, granulation tissue components, and angiogenic factors.
CONCLUSIONS Collagen Ia1 matricryptin p1158/59 facilitates LV remodeling post-MI by regulating scar formation
through targeted ECM generation and stimulation of angiogenesis. (J Am Coll Cardiol 2015;66:1364–74) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
ECM = extracellular matrix
LV = left ventricle
LVI = infarcted left ventricle
MI = myocardial infarction
MMP = matrix
metalloproteinase
TIMP = tissue inhibitor of
metalloproteinase
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1365D espite current treatment strategies, progres-sion to heart failure can occur in up to one-third of myocardial infarction (MI) patients
as a result of adverse remodeling of the collagenous
scar that replaces the necrotic myocardium (1).
Although excessive collagen deposition may result
in a stiff and noncompliant left ventricle (LV), insufﬁ-
cient collagen deposition may produce LV thinning
and dilation. Therefore, collagen levels are a critical
determinant of LV remodeling.
Cardiac extracellular matrix (ECM) dynamically
interacts with cells to regulate cell–cell and cell-ECM
interactions (2). ECM proteins modulate cell prolif-
eration, migration, adhesion, differentiation, and
survival (3). Although ECM protein synthesis is
controlled by growth factors, degradation is regulated
by proteases, particularly matrix metalloproteinases
(MMPs) (2). Collagen Ia1 is a major cardiac ECM
component of the post-MI scar and a substrate for
several MMPs, including MMP-1, -2, -8, and -9 (4).SEE PAGE 1375Davis et al. (5) introduced the term matricryptin to
describe proteolytically released biologically active
ECM fragments. Elastin-derived matricryptins induce
leukocyte activation, smoothmuscle cell proliferation,FIGURE 1 MMP-9 Cleaved Collagen Ia1
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(A) Mass spectrometry (MS) identiﬁed a naturally occurring collagen fra
cleavage of the C-terminus region of collagen Ia1 (arrow). The sequence
unique peptides identiﬁed. (B) Matrix metalloproteinase (MMP)-9 cleave
the helical C-terminal propeptide region.and MMP expression (6–8). Hyaluronan-
derived matricryptins interact with Toll-like
receptor-2 and -4 to modulate the inﬂamma-
tory and ﬁbrotic responses (9). The collagen
Ia1 matricryptin DGGRYY, amino acids 1200 to
1205, is a potent neutrophil activator, and the
tripeptide GHK (derived from both collagen
Ia2 and secreted protein acidic and rich in
cysteine [SPARC]) is chemotactic for mono-
cytes, macrophages, and mast cells and has
proangiogenic properties (10–12). Endostatin,
an MMP-9–released C-terminal fragment from
collagen XVIII, has antiangiogenic properties, whereas
matricryptins from collagen IV are both pro- and
antiangiogenic (13,14). MMP-9 cleaves collagen IVa3 to
produce tumstatin, which inhibits angiogenesis (15).
These reports suggest that ECM-generated matri-
cryptins may have important biological activity during
the healing cascade that follows MI.
Plasma MMP-9 levels directly correlate with LV
dysfunction post-MI, in both human and animal
models. In mouse models, MMP-9 deletion improves
LV remodeling and cardiac function post-MI (16).
Analysis of the wild-type LV infarct proteome showed
increased levels of a low-molecular-weight collagen
Ia1 fragment, compared with baseline day 0 levels9
59
37 aa
-Y repeats lacking
nal cleavage site
C-terminal
propeptide
gment in the infarcted left ventricle (LV), which was generated by
highlighted in yellow represents the sequence covered by MS and the
d collagen Ia1 at amino acids 1158/59 (arrow), which are upstream of
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1366(17). Collagen and collagen fragments are known
MMP-9 substrates, and MMP-9–null mice have better
LV function post-MI (16). However, whether this is a
result of accumulation of collagen matricryptins has
not been investigated. In this report, we evaluated
the mechanisms of generating a novel collagen frag-
ment and its roles in post-MI remodeling.
METHODS
Animal studies were performed according to pro-
tocols approved by the institutional animal care and
use committee at the University of Mississippi Medi-
cal Center. Written informed consent was collected
from all patients under protocols approved by the
University of Mississippi Medical Center institutional
review board committee. Experimental details are
provided in the Online Appendix.FIGURE 2 C-1158/59 Collagen Fragment Generated Post-MI
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(B) The C-1158/59 LVI time course with matrix metalloproteinase (MMP
MMP-9 was at its lowest post-MI level. Values are mean  SEM; n ¼ 8
C-1158/59. (C) By cleavage assays, both MMP-2 and MMP-9 generated
exposure to enzyme resulted in fragment degradation only by MMP-9. T
bracket indicates fragment degradation by MMP-9. (D) LVI protein extr
C-1158/59 collagen fragment (arrows). The plus sign indicates protein ex
sign indicates protein extracts without enzyme (n ¼ 3 biological replicaRESULTS AND DISCUSSION
Previously, we identiﬁed an w30-kDa C-terminal
collagen Ia1 fragment in the infarcted LV (LVI) at
7 days post-MI (Figure 1A) (17). Because MMP-9 is
prominent post-infarction, we performed cleavage
assays using a recombinant collagen Ia1 that contains
the N- and C-terminal regions and 66 Gly-X-Y triplet
repeats (residues Gln23-Lys277 þ Gly1094-Leu1464).
Mass spectrometry analysis of the cleavage products
revealed a new MMP-9 cleavage site between amino
acids 1158/59 in the C-terminal region, 37 amino acids
upstream of the collagen C-telopeptide (Figure 1B).
The generated C-collagen Ia1 fragment (C-1158/59) is
downstream of the canonical collagenase cleavage
site at Gly775-Ile776 (18).
Using an antibody speciﬁc for the 1158/59 cle-
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ction (MI), as detected by immunoblotting. (A) C-1158/59 time course
point; *p < 0.05 versus other days; #p < 0.05 versus same day LVC.
)-9. The C-1158/59 fragment accumulated in the LVI at day 7, when
/group; *p < 0.05 versus days 0 and 1; #p < 0.05 versus same day
the C-1158/59 collagen fragment; increased doses and prolonged
he arrow indicates the C-1158/59 fragment after cleavage by MMP-2;
acts from MMP-9-null mice at day 7 post-MI showed presence of
tracts (n ¼ 3 biological replicates) incubated with MMP-9; the minus
tes).
CENTRAL ILLUSTRATION Matricryptin Reduces LV Dilation Post-MI:
Diagram Depicting the Effects of Exogenous Delivery of p1158/59
Peptide to Mice Post-MI
 Lindsey, M.L. et al. J Am Coll Cardiol. 2015; 66(12):1364–74.
Following myocardial infarction (MI), the collagen fragment C-1158/59 is generated by
both matrix metalloproteinase (MMP)-2 and -9; however, it is degraded by MMP-9 when
MMP-9 levels peak. Endogenous delivery of the p1158/59 peptide, beginning at 3 h post-
MI and continuing for 7 days, improved the quality of extracellular matrix scar formed,
reduced ﬁbrosis, and promoted angiogenesis. This resulted in preserved left ventricular
(LV) geometry and reduced LV dilation post-MI.
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1367C-1158/59 fragment in the LVI and noninfarcted re-
mote control regions in a mouse MI model. C-1158/59
LVI levels robustly increased at day 7 post-MI; it
was >4-fold higher versus all earlier time-points
(all p < 0.05) and 3.5-fold higher than the day 7
LV remote noninfarcted control (p < 0.05) (Figure 2A,
Online Figure S1A). Post-MI, loss of myocytes and
contractility in the infarct region increases wall stress in
the remote LV and induces compensatory hypertrophy.
Our data suggest a small degree of collagen turnover in
the remote noninfarcted region in response to LV
remodeling post-MI. In the LVI, MMP-9 protein con-
centrations increased signiﬁcantly in the ﬁrst week post-
MI, returning to baseline (day 0) levels by day 7
(Figure 2B). This increase was consistent with our past
reports and with the timing of the generation of the
C-1158/59 fragment (19).
Because C-1158/59 fragment levels were higher at
day 7 post-MI, when MMP-9 levels were returning to
baseline, and were generated in the remote region
where MMP-9 expression is low, we expanded our
search to other MMPs that could cleave collagen at this
site. We tested the gelatinase MMP-2 that shares
highest homology and several substrates with MMP-9
and the collagenase MMP-8. MMP-11 was used as a
negative control, because this stromelysin does not
cleave collagen. Analysis of cleavage assays forMMP-2,
-8, -9, and -11 showed that both MMP-2 and -9, but not
MMP-8 or -11, can generate the C-1158/59 fragment
(Online Figures S1B and S1C). Our results show, for
the ﬁrst time, that MMP-2 and -9 cleaved collagen
Ia1 in the C-terminus at the amino acids 1158/1159.
Of note, increasing incubation times or MMP-9
doses (but not MMP-2) resulted in degradation of
the C-1158/59 fragment (Figure 2C). To conﬁrm this
in vivo, we quantiﬁed C-1158/59 levels from LVI pro-
tein extracts of MMP-9-null mice at day 7 post-MI,
incubated in the presence or absence of MMP-9.
We established that C-1158/59 is generated in the
MMP-9–null mice and incubation with MMP-9
degraded the fragment (Figure 2D). This conﬁrmed
that C-1158/59 can be generated by other MMPs and
suggested that decreased C-1158/59 levels at days 3
and 5 post-MI in the wild-type mice might be caused
by MMP-9 degradation.
IN VITRO TREATMENT WITH THE P1158/59 PEPTIDE.
To study the biological activity of the C-1158/59
fragment (Central Illustration), we synthesized a short
peptide containing the 15 amino acids downstream
of the cleavage site, beginning at amino acid 1159
(p1158/59; molecular weight 1,360.4 g/mol). The use
of small synthetic peptides to mimic the biological
activities of naturally occurring molecules has great
potential in overcoming difﬁculties associated withsynthesis of larger peptides. A short peptide is easier
to synthesize, purify, and concentrate. Although
technological advances have improved peptide syn-
thesis strategies, the purity and yield of synthesized
peptides can be limited by the sequence length.
Additionally, a small size peptide limits response
variability, which can occur with a longer peptide
that may possess multiple activities; by using a small
peptide, we ensured that cellular effects occurred as
a direct response to the cleavage site sequence and
not peptide structural properties. Cardiac ﬁbroblasts
were stimulated with increasing doses of p1158/59
or the spanning peptide negative control. The peptides
did not induce cell apoptosis or affect cell proliferation
(n ¼ 6 to 10/dose/assay) (Online Figures S2A and S2B).
FIGURE 3 Fibroblast Migration and Angiogenesis In Vitro
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(A) An automated wound healing assay showed increased migration of cardiac ﬁbroblasts after incubation with p1158/59. n ¼ 6/group; *p < 0.05
versus serum free; #p < 0.05 versus all other groups. (B) p1158/59 stimulated overexpression of the genes Lama1, Mmp-9, and Sparc. n ¼ 6/group;
*p < 0.05 versus serum free. (C) Stimulation with the p1158/59 peptide displayed strong proangiogenic properties by enhancing human umbilical vein
endothelial cell alignment and formation of a 3-dimensional tube network. n ¼ 3/condition, with each experiment run in duplicate, ﬁgures show repre-
sentative images. *p < 0.05 versus all other groups. FBS ¼ fetal bovine serum; MMP ¼ matrix metalloproteinase.
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1368We performed automated wound healing assays
and observed that wound closure rates were enhanced
with 1 mmol/l p1158/59 treatment and peaked at
22 h compared with untreated controls (Figure 3A).
Because proliferation rates were not different, the
increase in wound healing rates was due to increased
cell migration. Gene array analysis on the treated cells
revealed that Lama1 (laminin a1), Mmp-9, and Sparc
expression were all increased in cells treated with
p1158/59 (Figure 3B) (all p < 0.05). Laminin a1 is a
glycoprotein involved in basement membrane as-
sembly and architecture, and plays an important role
in cell migration through a3b1 and a6b1 integrins (20).
MMP-9 is also known to facilitate migration by
cleaving adhesion molecules, and SPARC has been
suggested to have antiadhesive properties, therefore
promoting cell migration by reducing cell–substrate
adhesion (21,22). Cell migration can be enhanced by
a directional cue, such as a chemoattractant, disrup-
tion of cell–cell contact (mechanical cue), internal
signaling cascades, and extracellular cues such as
ECM proteins, growth factors, and ligands (23). Our
data suggest that the p1158/59 matricryptin acts as
an extracellular cue and stimulates cell migrationby inducing overexpression of migration-mediator
factors. Similarly, others have reported collagen,
ﬁbronectin, and elastin-derived matricryptins that
stimulate directed cell migration of leukocytes and
ﬁbroblasts (24,25). Because p1158/59 induced ﬁbro-
blast MMP-9 expression, we looked at collagen levels
in the conditioned media to evaluate if MMP-9 incre-
ased collagen degradation. The p1158/59 peptide
did not affect levels of collagen secreted in vitro
(Online Figure S2C).
Human umbilical vein endothelial cells were used
to assess p1158/59 angiogenic properties. After
6 h, cells cultured in basal media and with the
negative control spanning peptide showed initial
stages of alignment and elongation, whereas cells
treated with p1158/59 showed robust induction of a
network of 3-dimensional capillary-like tubular
structures (p < 0.05) (Figure 3C). Our data indicated
that p1158/59 had strong proangiogenic in vitro
properties.
SYSTEMIC TREATMENT WITH THE P1158/59 PEPTIDE.
The in vitro data suggested that increased levels of
p1158/59 post-MI could lead to accelerated ﬁbroblast
migration into the infarcted area, which in turn would
FIGURE 4 Post-MI LV Dilation and Geometry
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Compared with the saline group, animals treated with p1158/59 post-MI showed reduced LV dilation, as evidenced by reduced end-diastolic
(EDD) and end-systolic (ESD) dimensions (A), and collagen deposition at day 7 post-MI (B). Using picrosirius red staining under polarized light,
saline produced thick yellow/red ﬁbers, and p1158/59 mostly thin green collagen ﬁbers. p1158/59 treatment did not affect collagen 1a1
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Abbreviations as in Figures 1 and 2.
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1369result in earlier deposition of granulation tissue that
could provide a sounder support for scar formation
and maturation. Thus, we treated mice with p1158/59
or saline vehicle control 3 h post-MI for a total of
7 days. Our aim was to determine whether an early
intervention strategy would stimulate scar formation
and angiogenesis to attenuate LV remodeling. There
was no difference in infarct size between groups
(p ¼ 0.15), indicating equal initial injury. This was
expected, because treatment was started 3 h post-MI,
after myocardial necrosis was fulminant.
In vivo, p1158/59 treatment resulted in attenuated
increased LV end-diastolic diameter and end-systolic
diameter post-MI compared with the saline group(p < 0.05) (Figure 4A), indicating that p1158/59 treat-
ment preserved LV structural integrity and reduced
LV dilation in the infarct region. Lower end-diastolic
dimensions indicate decreased stretching of the LV
muscle ﬁbers during preload, which in turn would
result in preserved LV structure. A study evaluating
chronic effects of the peptide would be beneﬁcial to
fully understand p1158/59 effects on cardiac function
post-MI. After MI, a person immediately encounters
decreased cardiac output and increased strain on
the heart. Prolonged inﬂammation and/or delayed
scar formation result in progressive LV wall thinning
and LV dilation, both associated with increased
incidence of heart failure and patient mortality.
TABLE 1 ECM and Adhesion Molecule Genes Overexpressed Following
p1158/59 Peptide Treatment*
Gene Name Protein Encoded Fold Change p Value
Adamts2 A disintegrin-like and metallopeptidase
with thrombospondin type-1 motif, 2
1.9 0.021
Cd44 CD44 antigen 2.4 0.003
Col3a1 Collagen type III, alpha-1 3.3 0.002
Col4a1 Collagen type IV, alpha-1 2.2 0.005
Col4a2 Collagen type IV, alpha-2 2.3 0.025
Col5a1 Collagen type V, alpha-1 4.5 <0.001
Ctgf Connective tissue growth factor 1.8 0.035
Ctnnb1 Catenin (cadherin associated
protein), beta-1
1.4 0.037
Ecm1 Extracellular matrix protein-1 3.0 0.015
Emilin1 Elastin microﬁbril interface-1 2.8 0.011
Entpd1 Ectonucleoside triphosphate
diphosphohydrolase-1
2.0 0.043
Fn1 Fibronectin-1 3.1 0.014
Icam1 Intercellular adhesion molecule-1 1.9 0.013
Itga3 Integrin, alpha-3 2.9 0.028
Itga4 Integrin, alpha-4 3.0 0.005
Itga5 Integrin, alpha-5 3.0 0.010
Itgam Integrin, alpha-m 2.1 0.008
Itgb1 Integrin, beta-1 1.4 0.018
Itgb2 Integrin, beta-2 4.1 0.005
Itgb3 Integrin, beta-3 2.8 0.005
Lama1 Laminin, alpha-1 2.1 0.048
Lamc1 Laminin, gamma-1 3.0 0.005
Mmp8 Matrix metallopeptidase-8 10.1 0.004
Mmp11 Matrix metallopeptidase-11 2.6 0.001
Mmp14 Matrix metallopeptidase-14 2.2 0.004
Sele Selectin, endothelial cell 2.6 0.015
Selp Selectin, platelet 3.0 0.021
Sgce Sarcoglycan, epsilon 2.8 <0.001
Sparc Secreted acidic cysteine rich glycoprotein 2.4 0.002
Spp1 Secreted phosphoprotein-1 6.5 0.014
Tgfbi Transforming growth factor, beta-induced 4.8 0.003
Thbs3 Thrombospondin-3 2.4 0.003
Tnc Tenascin C 3.7 0.013
Vcam1 Vascular cell adhesion molecule-1 2.2 0.009
Vcan Versican 1.4 0.029
*Treatment ran 7 days post-myocardial infarction; values compared with saline vehicle control
(n ¼ 6/group).
ECM ¼ extracellular matrix.
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1370Preserved chamber geometry and reduced dilation,
compared with the saline group, indicated better LV
contractility. Overall, our data demonstrated that
treatment with p1158/59 reduced LV dilation 7 days
post-MI, which opens therapeutic avenues for this
and other matricryptins. The literature describes
several studies in which matricryptins or other pep-
tides are used in MI models with different rates of
success. In a rat model, treatment with B-type natri-
uretic peptide for 7 days improved LV function at
8 weeks post-MI (26). Ladage et al. (27) delivered
recombinant periostin peptide into the pericardialspace post-MI in a pig model and observed a decrease
in infarct size and improved LV function compared
with controls.
We further investigated which changes were
occurring at the molecular level during scar formation
that could explain preserved LV structure after pep-
tide delivery. We determined that p1158/59-treated
mice showed less ﬁbrosis in the LVI, evidenced by
lower levels of collagen deposition in the infarcted
area at day 7 post-MI (p < 0.05 vs. saline) (Figure 4B).
We used picrosirius red staining for histological visu-
alization of collagen I and III ﬁbers (27). Sirius red dye
molecules align parallel to the long axis of collagen
molecules to enhance their natural birefringence (28).
Under polarized light, interstitial collagens show
different colors and intensities of birefringence.
Collagen I displays yellow or red thick, strongly bire-
fringent ﬁbers that are highly cross-linked, whereas
collagen III appears as thin, more compliant green ﬁ-
bers with lower birefringence (28). Of note, although
the saline group showed thick, strongly birefringent
ﬁbers consistent with collagen I deposition, p1158/59
treatment resulted in thin green ﬁbers with lower
birefringence, suggestive of increased collagen III
deposition. By gene array, we conﬁrmed that p1158/59
stimulated Col3a1 expression by 3.3-fold (Table 1).
Collagen III is the ﬁrst ﬁbrillar collagen produced by
ﬁbroblasts during the proliferative phase after injury,
later being replaced by collagen I, which is stiffer and
less compliant than collagen III (29). These data sug-
gest that p1158/59 stimulated collagen III deposition,
resulting in a decreased ratio of collagen I/collagen III,
which would generate a less stiff scar and may explain
the better LV geometry (Figure 4C). Fetal tissues show
increased expression of collagen III compared with
adult tissue, which has led some to hypothesize that
collagen III is a main contributor to the scarless
phenotype observed in the early stages of gestation
(30). We further looked at the expression of MMPs
and tissue inhibitors of metalloproteinases (TIMP),
because MMP activity and MMP/TIMP ratios can
determine ECM turnover and remodeling (31). At
7 days post-MI, only MMP-8, -11, and -14 expression
were increased in the peptide-treated group compared
with saline (Online Tables S1 and S2). Our data
demonstrated that p1158/59 treatment improved scar
formation through reduced stiffness and ﬁbrosis,
and preserved LV structure post-MI.
Treatment with p1158/59 induced 35 ECM- and
adhesion molecule-associated genes in the infarct
region compared with saline-treated MI controls, out
of 85 genes examined (Table 1) (Online Tables S1
and S2 shows the 50 unaltered genes). Expression of
Adamts2 was increased 2-fold in the treated group
FIGURE 5 p1158/59-Stimulated Vessel Formation In Vivo
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p1158/59 peptide treatment increased vessel number in the LV 7 days post-
MI, as indicated by increased binding of lectin 1 (GSL-1). (A) Endothelial cell
numbers were quantiﬁed by immunohistochemistry in 5 random ﬁelds per
section. n ¼ 5 to 6/group; *p < 0.05 versus saline. Arrows indicate positive
cells. (B) Protein levels were quantiﬁed by densitometry (top immunoblot)
and normalized to the total protein (bottom immunoblot) in each respective
lane. n ¼ 5 to 6/group; *p < 0.05 versus saline. Other abbreviations as in
Figures 1 and 2.
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1371compared with the saline control (p < 0.05).
ADAMTS2 cleaves the N-terminal propeptides of
collagen types I and III during collagen maturation,
therefore playing a key role in collagen turnover.
Connective tissue growth factor (CTGF) expression
was elevated in the treated group, CTGF promotes
ﬁbroblast proliferation, migration, adhesion, and
ECM and vessel formation (32). CTGF directly binds
to integrin receptors and proteoglycans, and thus
participates in signal transduction events. Most
biological activities of matricryptins are mediated by
integrins, proteoglycans, and growth factor receptors
(14). Endostatin (MMP-2 generated) and tumstatin
(MMP-9 generated) exert their angiogenic effects by
interacting through avb3 integrins, whereas angio-
genic laminin peptides bind to avb3 and a5b1 integrins
(33,34). Table 1 shows overexpression of Itga5 (integrin
alpha-5), Itgb1 (integrin beta-1), and Itgb3 by p1158/59
treatment, suggesting that this matricryptin may be
mediated by these integrins.
Our data suggest p1158/59 reduced the stiffness of
the provisional matrix post-MI by enhancing expres-
sion of collagen III and CTGF, which would reduce
ﬁbrosis during early wound healing. The accelerated
formation of a stable matrix may further support cell
migration, adhesion, and vessel formation, which
would contribute to preserved LV structure and
reduced LV dilation.
Animals that received p1158/59 for 7 days post-MI
showed enhanced expression of Col4a1, Col4a2, and
Lama1 compared with the saline MI group (Table 1)
(p < 0.05 for all). These genes are components of
the basement membrane and stimulate angiogenesis.
Collagen IV provides a stable substrate for vessel for-
mation and promotes and regulates the formation,
extension, and stabilization of microvessels during
angiogenesis. Similarly, Lama1 stimulates angiogen-
esis and is critical for vessel integrity. Therefore,
increased collagen IV and Lama1 expression by p1158/
59 may promote angiogenesis and quicker formation of
adaptive capillary growth during LV remodeling.
Extracellular matrix protein-1 (Ecm1), a secretory
glycoprotein that promotes angiogenesis by inducing
endothelial cell proliferation and neovessel formation,
was overexpressed in the p1158/59 group (Table 1).
Interestingly, this protein has been shown through
high-afﬁnity protein–protein interactions to inhibit
MMP-9 activity (35).Mmp-11, also signiﬁcantly elevated
in the p1158/59-treated animals (Table 1), is highly
associated with cell migration and invasion (36).
To validate what we observed at the gene level, we
quantiﬁed by immunoblotting and immunohisto-
chemistry Griffonia (Bandeiraea) simplicifolia lectin I
(GSL-1), which speciﬁcally binds to endothelial cells(37). Mice treated with p1158/59 displayed higher
binding of GSL-1 and increased vessel numbers in both
the remote and infarct regions compared with saline
(Figures 5A and 5B) (p < 0.05), indicative of increased
vascularization. The remote region maintains per-
fusion after MI; however, remodeling occurs due
to changes in wall strain patterns that lead to rapid
regression of cardiac mass through cardiomyocyte
FIGURE 6 C-1158/59 Collagen Fragment Levels
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1372atrophy. The cardiomyocytes respond to the increased
load by increasing protein synthesis, and the resulting
hypertrophic responsemay lead to relative insufﬁcient
vascular growth. To assess whether the increased
vessel numbers observed with p1158/59 treatment
were due to myocyte atrophy, we quantiﬁed the
expression of the Forkhead Box O3 (Foxo3), a tran-
scription factor that, when activated, promotes myo-
cyte atrophy and autophagy (38,39). No difference was
observed in Foxo3 activation between groups (Online
Table S2), giving evidence that p1158/59 treatment
stimulated angiogenesis did not occur through Foxo3
signaling. Increased angiogenesis in both remote
and infarct regions may offer the necessary car-
dioprotection to mitigate LV dysfunction post-MI.
Taken together, our results established that p1158/59matricryptin had robust proangiogenic properties
in vivo. Endorepellin, a perlecan-derived matri-
cryptin, displayed proangiogenic and neuroprotective
properties in a rodentmodel of ischemic stroke and has
shown promising results for the treatment of stroke
(40). It would be interesting to determine whether the
use of proangiogenic matricryptins such as p1158/59 in
the settings of ischemia and compromised healing,
such as diabetic wounds, could delay or even reverse
the tissue necrosis caused by poor vascularization and
chronic inﬂammation. Further studies are necessary
for a deeper understanding of the modes of action. For
example, doses to be administered in vivo require
careful optimization because many angiogenic factors
display biphasic response curves. Another critical
issue is the dual activities of some matricryptins,
which depend on environment, concentration, and/or
cell type. Moreover, time and duration of intervention
is also important. In our study, we delivered the
matricryptin for 7 days, beginning very early post-MI,
but long-term effects will need to be studied.
Finally, we quantiﬁed the C-1158/59 fragment in
the plasma of healthy subjects and patients at 24 to
48 h post-MI. Patient characteristics are in Online
Table S3. Of interest, the post-MI patients showed
reduced levels of C-1158/59 (Figure 6A) (p < 0.05 vs.
healthy controls), consistent with high MMP-9 levels
at this time. Plasma MMP-9 levels peak at day 1 in
post-MI patients, which may increase collagen frag-
ment degradation (41). This decrease may also reﬂect
a difference between sampling from the tissue and
plasma. In post-MI patients, the plasma levels of the
C-1158/59 fragment negatively correlated with E/e0
ratios (r ¼ 0.332; p ¼ 0.025) (Figure 6B). An E/e0
ratio <8 is indicative of normal ﬁlling pressures,
whereas an E/e0 >15 is indicative of markedly ele-
vated ﬁlling pressures (42). Thus, our data suggest
that lower levels of C-1158/59 collagen fragment
correlated with reduced cardiac function.
STUDY LIMITATIONS. One limitation was the time
difference in sampling between the mouse and
human MI studies. Another was that we collected
peripheral venous plasma samples, but did not collect
coronary sinus levels, which would have allowed us
to evaluate the myocardium as a direct source of the
peptide. Further studies will be necessary to investi-
gate the natural occurrence of this collagen fragment
at later time points and its effects on long-term
cardiac remodeling.
CONCLUSIONS
We have identiﬁed a novel collagen Ia1 cleavage site
and the generation of a matricryptin downstream of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Following MI,
collagen I, a major component of the cardiac extracellular
matrix, is proteolytically cleaved by matrix metalloproteinases
into fragments known as matricryptins that mediate
left ventricular remodeling in a mouse model by enhancing
ﬁbroblast activity, basement membrane and granulation tis-
sue integrity and angiogenesis.
TRANSLATIONAL OUTLOOK: Clinical studies are needed to
assess the safety and efﬁcacy of matricryptins and other frag-
ments that modulate cardiac remodeling at the molecular level in
patients recovering from MI.
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1373this site, p1158/59, stimulated in vitro and in vivo
wound healing. Our data show that p1158/59 is a
biologically active molecule with potent proangio-
genic properties and has direct effects on the quality
of scar tissue post-MI by promoting early ECM depo-
sition. Together, these effects preserved LV structure
and geometry, resulting in reduced LV dilation
post-MI. These data strongly promote this matri-
cryptin as a molecule of interest to treat adverse LV
remodeling.
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